central contributor of instability of atherosclerotic plaque. However, how CHOP is regulated in atherosclerotic plaques is poorly studied.
AMPK (AMP-activated protein kinase) is a well-characterized regulator of cellular energy status. AMPKα1 is the predominant isoform of AMPKα in vascular cells, including endothelial cells, vascular smooth cells, and monocytes/macrophages. 16 However, both AMPKα1 and AMPKα2 have been demonstrated to regulate vascular cell function. [17] [18] [19] [20] [21] Genetic deletion of Ampkα2 promotes atherosclerosis in vivo, likely via aberrant endoplasmic reticulum stress. 22 Whether or not dysfunctional AMPK promotes atherosclerotic plaque vulnerability remains unknown. The aim of the present study was to test whether AMPK reduces atherosclerotic plaque vulnerability by promoting CHOP ubiquitination and degradation. Here, we report that phosphorylation of CHOP at serine 30 (Ser30) by AMPKα1 triggers CHOP degradation, resulting in reduced macrophage apoptosis and subsequent ameliorated plaque vulnerability in vivo.
Methods

Murine Ligation and Cuff-Triggered Neointimal Disruption Model
A well-characterized murine model was used to assay neointimal formation and disruption, as described previously. 15, 23, 24 Briefly, 9-week-old male Apoe −/− , Apoe −/− /Amp kα1 −/− , and Apoe −/− /Ampkα2 −/− mice were anesthetized with an intraperitoneal injection of 100 mg/kg ketamine-HCl and 10 mg/kg xylazine-HCl, and their right common carotid artery was ligated proximal to the bifurcation. Four weeks after ligation, a polyethylene cuff (427410; BD Biosciences, San Jose, CA) was placed around the ligated right common carotid artery. At 4 days after cuff placement, the right common artery was collected, and the intracuff lesions were evaluated by hematoxylin-eosin staining. The incidence of injury-induced neointimal disruption was calculated. For in vivo siRNA transfection, 25 15 μg of scramble Stealth RNAi siRNA (12935-112; Invitrogen, Grand Island, NY) or Stealth Chop-specific siRNA (1320001; Invitrogen, Grand Island, NY) dissolved in 30% pluronic gel solution (P2443; Sigma-Aldrich, St Louis, MO) was perivascularly delivered to the ligated and cuffed right common carotid artery of the Apoe −/− mice starting 7 days before tissue collection. After 7 days of siRNA delivery, the carotid arteries were collected to analyze the incidence of neointimal disruption, and the efficiency of siRNA delivery to the carotid artery was demonstrated by Western blot analysis.
Statistical Analysis
Quantitative values are expressed as the mean±SEM and represent data from at least 3 independent experiments. The difference between 2 groups was analyzed by Student's t test. The difference among >2 groups was analyzed by 1 way analysis of variance, followed by Newman-Keus multiple comparison test, and comparisons of different parameters between each group were made by 2-way ANOVA analysis followed by Bonferroni posttests. For incidence of injury-induced neointimal disruption, groups were compared with Chi-square test (3 groups) or Fisher exact test (2 groups) . P values of <0.05 were considered statistically significant.
An expanded Materials and Methods are available in the Online Data Supplement.
Results
Ampkα1 Deletion Promotes Macrophage Apoptosis
Lipid-overloaded macrophages are a major cellular component of advanced atherosclerotic plaque. Overwhelming evidence suggests that atherosclerotic plaques become vulnerable to rupture when apoptotic macrophages trigger a local inflammatory response and matrix proteinase activation. [6] [7] [8] [9] To test whether AMPKα modulates macrophage apoptosis, we first detected the effect of genetic deletion of Ampkα on apoptosis in macrophages. As shown in Figure 1A , the number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells in Ampkα1 −/− bone marrow-derived macrophages (BMDMs) was significantly higher compared with wild-type (WT). In contrast, the number of TUNEL-positive BMDMs from Ampkα2 −/− mice did not vary from WT mice. Consistent with this observation, the levels of both cleaved caspase 3 and poly(ADP-ribose) polymerase, 2 well-characterized markers for apoptotic cells, were significantly higher in the BMDMs isolated from Ampkα1 
AMPKα1 Inversely Regulates CHOP Protein Levels in Macrophages
It has been reported that CHOP-induced macrophage apoptosis promotes atherosclerotic plaque rupture. 15 Given that AMPKα1 is the predominant AMPKα isoform in human and mouse macrophages, 18 we set out to determine whether AMPKα1 regulates apoptosis by altering the levels of CHOP in macrophages. To test the regulatory role of AMPKα1 in CHOP-induced macrophage apoptosis, mouse macrophagelike cell line RAW264.7 cells were transfected with scramble, Ampkα1-specific, or Chop-specific siRNA. As shown in Online Figure I , transfection of Ampkα1 siRNA markedly increased the levels of CHOP and cleaved caspase 3. Scramble siRNA had no effect. Chop siRNA reversed the increased cleaved caspase 3 level by Ampkα1 siRNA (Online Figure I) . Therefore, we demonstrated that elevated caspase 3 cleavage in Ampkα1 siRNA-treated cells is CHOP-dependent by co-transfecting Chop siRNA with Ampkα1 siRNA. In contrast, the transfection of Chop siRNA without co-transfection with Ampkα1 siRNA did not alter cleaved caspase 3 levels compared with Figure 2A showed the deletion of Ampkα1 but not Ampkα2 significantly increased CHOP protein levels in macrophages. Consistent with this, BMDMs from Ampkα1 −/− mice but not WT or Ampkα2 −/− mice exhibited higher mRNA levels of well-known CHOP target genes, such as Wars, Sars, Trib3, and Ero1α, 26 suggesting that Ampkα1 deletion increases CHOP activity in macrophages (Online Figure  II) . Furthermore, we demonstrated that activation of AMPK with either AICAR (5-aminoimidazole-4-carboxamide ribonucleoside; Figure 2B ) or A769662 ( Figure 2C ) lowered CHOP levels in macrophages in a time-dependent manner. Conversely, inhibiting AMPK activity with compound C led to an upregulation of CHOP levels in a time-dependent manner ( Figure 2D ). Overall, our results support the hypothesis that AMPKα1 is an inverse regulator of CHOP.
To assess whether increased CHOP protein levels resulting from AMPK inhibition are because of an increase in Chop mRNA levels, we conducted quantitative real-time reverse transcriptase polymerase chain reaction to determine Chop mRNA in BMDMs isolated from WT, Ampkα1 −/− and Ampkα2 −/− mice. As shown in Online Figure III , similar levels 
AMPK Decreases CHOP Protein Stability
To explore how AMPK activation decreases CHOP protein levels, cycloheximide-pretreated macrophages were exposed to AICAR, and the steady-state levels of CHOP were measured by Western blot analysis. As shown in Figure 3A , AMPK activation by AICAR significantly increased the degradation of CHOP. Transfection of Ampkα1-specific siR-NA but not scramble siRNA prevented CHOP degradation ( Figure 3B ). Consistent with these results, genetic deletion of Ampkα1 in BMDMs inhibited CHOP degradation when compared with WT BMDMs (Figure 3C ), indicating that AMPKα1 is an important regulator of CHOP protein stability in macrophages.
AMPKα1 Phosphorylates CHOP at Ser30
CHOP has been reported to be phosphorylated by p38 MAP kinase and casein kinase 2.
27,28 AMPK is a well-known threonine/serine protein kinase. Therefore, we hypothesized that AMPKα1 phosphorylates CHOP to control its stability. Computer alignment studies indicated that Ser30 within CHOP to be a potential optimal AMPKα1 substrate motif ( Figure 4A ). 29 As shown in Figure 4B , AMPKα1 coimmunoprecipitates with CHOP in macrophages. Furthermore, we observed costaining of AMPKα1 and CHOP in BMDMs ( Figure 4C ). Finally, an in vitro kinase assay showed that both endogenous immunoprecipitated AMPKα1 and exogenous recombinant protein AMPKα1 phosphorylates CHOP (p-CHOP) at Ser30 ( Figure 4D and 4E) .
We next established if AMPK-dependent Ser30 phosphorylation of CHOP occurred in intact cells. Macrophages were exposed to either AICAR or A769662 at the times indicated. As depicted in Figure 4F and 4G, AMPK activator AICAR or A769662 markedly increased p-CHOP at Ser30 at 8 hours. Further, prolonged incubation (≤24 hours) increased levels of p-CHOP at Ser30. Conversely, inhibition of AMPK with compound C, a potent AMPK inhibitor, time-dependently lowered the levels of p-CHOP at Ser30 ( Figure 4H ). In line with these results, BMDMs isolated from Ampkα1 
CHOP Phosphorylation at Ser30 Is Required for AICAR-Induced Downregulation of CHOP
To determine whether phosphorylation of CHOP at Ser30 is involved in the AICAR-induced downregulation of CHOP, we generated a phosphorylation-deficient Chop mutant (Ser30 is replaced by alanine, S30A) and a phosphomimetic Chop mutant (Ser30 is replaced by glutamic acid, S30E). RAW264.7 cells were transfected with full-length WT Chop (WT), phosphorylation-deficient Chop (S30A), or phosphomimetic Chop (S30E). Forty-eight hours after the transfection, cells were treated with or without AICAR for 12 hours. 
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The Chop-S30A mutant alone did not alter CHOP protein levels ( Figure 4K ). As expected, AICAR reduced CHOP levels in WT-transfected macrophages, whereas AICAR did not alter CHOP protein levels in macrophages transfected with Chop-S30A ( Figure 4K ). Conversely, mutation of the phosphomimetic Chop-S30E variant markedly lowered the levels of CHOP compared with CHOP in WT-transfected macrophages ( Figure 4L ). AICAR treatment did not cause further reduction of CHOP in cells transfected with the Chop-S30E mutant ( Figure 4L ). Taken together, these data indicate that phosphorylation of CHOP at Ser30 is required for AICARinduced degradation of CHOP.
AMPK Increases CHOP Ubiquitination
Three major protein degradation pathways exist in mammalian cells: the proteasome, the lysosome, and the autophagosome. Cellular inhibitor of apoptosis protein-1 is reported to promote CHOP degradation through the proteasome pathway in β cells. 30 We next determined which pathway is involved in AMPK-mediated CHOP degradation in macrophages. To assess which pathway mediates CHOP degradation in macrophages, cells were treated with either the proteasome inhibitor MG-132, the lysosome inhibitor chloroquine, or the autophagy inhibitor 3-MA. As shown in Figure 5A , neither chloroquine nor 3-MA altered CHOP levels. However, MG-132 led Figure 5B ). Taken together, these results support the hypothesis that CHOP degradation is mediated by the proteasome in macrophages.
We next determined whether AMPK activation promotes CHOP ubiquitination. Macrophages were pretreated with MG-132 for 30 minutes before AICAR treatment. AICAR promoted CHOP ubiquitination with or without MG-132 ( Figure 5C ). In contrast, the levels of ubiquitinated CHOP in BMDMs of Ampkα1 −/− mice were markedly lower than their counterparts from WT mice ( Figure 5D ). Collectively, these data indicate that AMPK activation enhances CHOP ubiquitination.
Phosphorylation of CHOP at Ser30 Positively Regulates CHOP Ubiquitination
We assayed if AMPK-mediated CHOP phosphorylation at Ser30 is required for CHOP ubiquitination. RAW264.7 cells were transfected with either full-length WT Chop (WT) or Chop mutants (Chop-S30A and Chop-S30E). Compared with WT Chop, phosphomimetic Chop-S30E showed elevated ubiquitination, whereas the phosphorylation-deficient Chop-S30A mutant exhibited reduced ubiquitination ( Figure 5E ). These data suggest that CHOP phosphorylation at Ser30 is important for CHOP ubiquitination and subsequent degradation.
To further examine the key role of Ser30 phosphorylation on CHOP stability, cycloheximide pulse-chase experiments were done with both the S30E and S30A mutants of Chop in RAW264.7 cells. As shown in Figure 5F , the half-life of Chop-S30A (>8 hours) was twice as long as that of the Chop-S30E. These data further confirm that CHOP Ser30 phosphorylation leads to CHOP ubiquitination and degradation.
Ampkα1 Deletion Aggravates Injury-Induced Neointimal Disruption in Apoe −/− Mice
Given that CHOP plays an important role in promoting atherosclerotic instability 15 and our above mentioned results showed AMPKα1 downregulates CHOP level in vitro, we reasoned that AMPKα1 activation could reduce injury-induced neointimal disruption by lowering CHOP in mice in vivo. To test the effects of AMPK-CHOP pathway in plaque stability, we generated the right carotid artery ligation plus cuff placement model, a well-characterized model for studying injuryinduced neointima stability. 15 /Ampkα2 −/− mice, cuffs were placed in the ligated right carotid arteries for 4 days before mice were euthanized for further analysis. As shown in Online Figure  V , serum triglycerides and total cholesterol were comparable among the 3 groups. After ligation and cuff placement, the right carotid arteries of most of the mice in all groups developed neointimal plaque, and mean lesion areas were similar between the groups (Table) , suggesting that macrophage AMPKα1 deletion did not impact the sizes of injury-induced neointimal lesions.
Next, we assayed the roles of macrophage AMPKα1 in maintaining neointimal plaque stability. It is commonly believed that in neointimal lesions, both collagen and vascular smooth muscle cells (VSMCs) promote stabilization of the neointima, whereas macrophage destabilizes the plaques. 31, 32 To this end, we measured the contents of collagen, VSMC, and macrophages in neointimal plaques. As depicted in Figure 6A , collagen contents, measured by picrosirius red staining, were significantly lower in the neointima of Apoe Figure 6B ). Taken together, these results indicate that AMPKα1 deletion promotes instability of the neointimal lesions.
It was important to assess if macrophage AMPKα1 deletion promoted neointimal disruptions in vivo. Disrupted neointima is defined as neointima with mural or occlusive thrombus. 24 Although incidence of neointimal disruption was similar between Apoe −/− and Apoe −/− /Ampkα2 −/− mice (54.2% versus 52.6%, respectively; Table) , the incidence of disrupted neointima was significantly increased in the Apoe
−/− mice compared with Apoe −/− mice (54.2% versus 85.7%, respectively; Table), suggesting that AMPKα1 plays an essential and specific role in neointimal stability but not in neointimal lesion size. Taken together, deletion of Ampkα1 but not Ampkα2 promotes the injury-induced neointimal disruption in Apoe −/− mice. To strengthen our conclusion, we developed another murine atherosclerotic model. Apoe −/− and Apoe −/− /Ampkα1 −/− mice were fed Western diet for 10 weeks, and the stability of atherosclerotic plaques in mouse brachiocephalic arteries was determined. As shown in Online Figure VIIA , the Figure VIIB) . However, mean lesion areas showed no significant difference between groups (Online Figure VIIB) . Taken together, these results suggest that Ampkα1 deletion reduces the stability of brachiocephalic artery atherosclerotic plaques in Apoe −/− mice in vivo.
Ampkα1 Deletion Promotes Apoptosis in Neointimal Plaque
To detect whether apoptosis was involved in the AMPKα1-dependent neointimal disruption, we next assessed apoptosis in the injury-induced neointimas of Apoe 14 Because macrophages are ones of the main cellular components in injury-induced neointima, we next stained the ruptured plaque sections with both TUNEL and macrophage marker CD68. As shown in Online Figure  VIII , the TUNEL-positive staining colocalized with the CD68 staining, and overlap coefficient for TUNEL with CD68 is >90%, indicating that apoptosis mainly occurred in macrophages within the ruptured plaque. Furthermore, the levels of cleaved caspase 3 were significantly higher in the atherosclerotic plaques of Apoe −/− mice. Ampkα1 deletion decreases CHOP phosphorylation, which leads to reduced CHOP ubiquitination/CHOP degradation. As a result, CHOP levels increase, which subsequently triggers increased macrophage apoptosis and accelerates injury-induced neointimal disruption. AMPK indicates AMP-activated protein kinase; Apoe, apolipoprotein E; CHOP, C/EBP homologous protein; and p-CHOP, phosphorylated CHOP. 
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October 28, 2016 abated CHOP protein expression in the ligated and cuffed carotid arteries ( Figure 7C ). However, compared with scramble siRNA-treated carotid arteries, the Chop siRNA markedly decreased the incidence of neointimal disruption in Apoe −/− mice ( Figure 7D ; Online Table III) . Compared with scramble siR-NA-treated carotid arteries, the transfection of Chop-specific siRNA in treated-Apoe −/− mice markedly increased collagen contents and suppressed macrophage accumulation and apoptosis (Online Figures XIA, XIB, and XII) . As expected, in vivo knockdown of Chop by siRNA had no effect on VSMC contents (Online Figure XIC) . Taken together, these results indicate that CHOP induces carotid artery neointimal disruption of Apoe −/− mice.
Discussion
In this study, we have demonstrated for the first time that AMPK activation promotes CHOP degradation via ubiquitination and that genetic deletion of Ampkα1 causes CHOP accumulation. This results in aberrant macrophage apoptosis and consequent injury-induced neointimal disruption in vivo.
Mechanistically, AMPKα1 binds with CHOP and phosphorylates CHOP at Ser30. This phosphorylation triggers CHOP ubiquitination and consequent degradation by the proteasome. The principal findings of this study are as follows: (1) AMPKα1 inhibition increases macrophage apoptosis; (2) AMPKα1 inhibition-induced macrophage apoptosis is CHOPmediated; (3) AMPK activation reduces and AMPK inhibition increases CHOP protein levels in macrophages; (4) AMPKα1 phosphorylates CHOP at Ser30; (5) CHOP phosphorylation at Ser30 initiates CHOP ubiquitination and subsequent CHOP degradation in the proteasome; (6) genetic inhibition of Ampkα1 promotes in vivo injury-induced neointimal disruption in mice via increase in CHOP accumulation; and (7) local inhibition of Chop by siRNA decreases the incidence of neointimal disruption in Apoe −/− mice. Thus, we conclude that AMPKα1 activation might prevent injury-induced neointimal disruption by promoting proteasomal degradation of CHOP in macrophages ( Figure 7E) .
The most important finding of this study is that we have demonstrated for the first time that AMPKα1 activation suppresses injury-induced neointima disruption by suppressing CHOP-dependent macrophage apoptosis. Compared with either Apoe −/− or Apoe
/Ampkα2
−/− mice, the incidence of neointimal disruption with thrombus was significantly increased in Apoe
−/− mice. Macrophage apoptosis in the advanced lesion is one of the most important inducers of atherosclerotic plaque vulnerability. 33, 34 Kolodgie et al reported an increased number of apoptotic macrophages at sites of plaque disruption compared with those in intact fibrous caps. 8 We were able to show that macrophage infiltration and macrophage apoptosis in injured carotid arteries were significantly higher in Apoe −/− /Ampkα1 −/− mice compared with those in Apoe −/− or Apoe −/− /Ampkα2 −/− mice and that apoptosis-suppressing effects of AMPK in macrophages is important in maintaining the stability of injury-induced neointimas. These results are consistent with a published clinical study in which lesion macrophages are the primary apoptotic cell type involved in generating rupture-prone plaques of the human carotid artery. 14 A key finding of this study is that AMPK promotes CHOP protein degradation by enhancing CHOP ubiquitination. First, we found that AMPK activation accelerated CHOP protein decay. Furthermore, this AMPK-accelerated CHOP degradation was abolished with Ampkα1 knockdown or genetic deletion. In addition, we found that AMPKα1 phosphorylated CHOP Ser30. CHOP degradation is mediated by the proteasome pathway, 30 and we confirmed this in macrophages. Next, we addressed the question whether CHOP phosphorylation at Ser30 promoted its ubiquitination and then degradation. The phosphomimetic CHOP-S30E showed elevated levels of ubiquitination compared with WT CHOP, while phosphorylationdeficient mutant CHOP-S30A showed reduced ubiquitination compared with WT CHOP. This suggests that phosphorylation of CHOP at Ser30 positively regulates CHOP ubiquitination. Furthermore, CHOP expression was significantly higher in atherosclerotic plaques isolated from Apoe mice. This result strongly suggests that Ser30 phosphorylation of CHOP by AMPKα1 promotes CHOP ubiquitination and degradation. Importantly, CHOP accumulation promotes the disruption of the injury-induced carotid neointima in Apoe −/− mice. AMPK might also be important in maintaining atherosclerotic plaque stability. Although mouse atherosclerotic plaques are, in general, stable and there is no commonly accepted mouse models to study atherosclerotic plaque stability, the atherosclerotic plaques in brachiocephalic arteries are considered as a well-characterized site for studying plaque stability. 35, 36 Indeed, we found that the aortic lesions of brachiocephalic arteries of Apoe 
/Ampkα1
−/− mice were less than those in the plaques of the Apoe −/− mice, suggesting a negative association between CHOP and p-CHOP (Ser30) in vivo in Western diet-fed atherosclerotic mice. Overall, these results strongly support that Ampkα1 deficiency exacerbates atherosclerotic plaque vulnerability.
Atherosclerotic plaque rupture is a common pathogenic mechanism for coronary heart diseases and stroke. Our results strongly support the hypothesis that AMPK activation is a novel target in preventing atherosclerotic plaque rapture. Beside its beneficial effects on atherosclerotic plaque stability, AMPK activation inhibits the initiation and progression of atherosclerosis in vivo 22, 37, 38 via its protective effects in endothelial cells 39 and VSMCs. 40 Consistently, metformin, a well-characterized AMPK activator, has been demonstrated to effectively reduce adverse cardiovascular events and mortality in patients with type II diabetes mellitus. 41 In summary, our study has demonstrated that Ampkα1 deficiency increases injury-induced neointimal disruption in Apoe −/− mice, and AMPKα1 phosphorylates CHOP at Ser30 to promote CHOP ubiquitination and degradation. Our results indicate that AMPK may be a novel therapeutic target for promoting atherosclerotic plaque stability and the prevention of acute coronary heart disease and stroke.
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Phosphorylation of C/EBP homologous protein (CHOP) by the AMP-activated protein kinase alpha 1 in macrophages promotes CHOP degradation and reduces injury-induced neointimal disruption in vivo
Xiaoyan Dai 
Animals
ApoE -/-(C57BL/6 background) mice were purchased from Jackson Laboratories (Bar Harbor, Maine). AMPK1 and AMPK2 homozygous knockout mice (AMPK1 -/-or AMPK2 -/-) were generated as previously described. 1 To breed ApoE
mice were backcrossed into a C57BL/6 genetic background for at least ten generations before crossing them with ApoE Cell culture RAW264.7 cells were from ATCC (Manassas, VA). Cells were cultured at 1.0×10 6 per ml Dulbecco's Modified Eagle's Medium with 10% FBS under 95% air and 5% carbon dioxide (CO2) at 37.0 °C.
Generation of BMDMs
Primary bone marrow-derived macrophages (BMDMs) were prepared by flushing the bone marrow of the femur and tibia of mice. Cells were cultured with complete RPMI-1640 medium supplemented with mouse M-CSF recombinant protein (50 ng/ml, eBioscience) for 5-7 days.
2
Apoptosis analysis
Terminal deoxynucleotidyl transferase-mediated nick-end labeling assay (TUNEL) for BMDMs and mouse carotid artery fresh-froze sections were carried out according to a commercially available kit from Roche Applied Science (Indianapolis, Ind). Nuclei were stained with DAPI. OLYMPUS BX51 or Zeiss 710 fluorescent microscope was applied. The percentage of TUNEL-positive nuclei was calculated.
Western blot analysis
Cell lysates or tissue homogenates were subjected to Western blot analysis, as described previously. 3 The protein content was assayed by BCA protein assay reagent (Pierce, USA). 50 μg protein was loaded to SDS-PAGE and then transferred to PVDF membrane. Membrane was incubated with a 1:1000 dilution of primary antibody, followed by a 1:2000 dilution of horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized by ECL (GE Healthcare). The intensity (area × density) of the individual bands on Western blots was measured by densitometry (model GS-700, Imaging Densitometer; Bio-Rad). The background was subtracted from the calculated area. We used control as 100%.
Transfection of siRNA into RAW264.7 cells
In vitro, transient transfection of CHOP siRNA (sc-35438) and AMPK1 siRNA (sc29674) was carried out according to Santa Cruz's protocol. Briefly, the siRNAs were dissolved in siRNA buffer to prepare a 10 µmol/L stock solution. RAW264.7 cells grown in 6 well plates were transfected with siRNA in transfection medium (Gibco) containing liposomal transfection reagent (Lipofectamine RNAiMax; Invitrogen). For each transfection, 100 µl transfection medium containing 4 µl siRNA stock solution was gently mixed with 100 µl transfection medium containing 4 µl transfection reagent. After a 30-min incubation at room temperature, siRNA-lipid complexes were added to the cells in 800 µl transfection medium, and cells were incubated with this mixture for 6 h at 37 °C. The transfection medium was then replaced with normal medium, and cells were cultured for 48 h.
Half-life of CHOP protein degradation determination
Cells were incubated with a protein translation inhibitor cycloheximide (CHX, 5 μg/ml) to block de novo protein synthesis and treated with or without AICAR (1 mmol/L) for indicated time. Western blot analysis and quantification of CHOP/DDK level were performed.
RNA extraction, reverse transcriptase-polymerase chain reaction (RT-PCR), and quantitative PCR (qPCR)
Cell total RNA was extracted using the TRI Reagent® Solution (AM9738; Life technologies) and 1 µg of RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis Kits (Bio-Rad, Hercules, CA). PCR amplification was performed using the SYBR PCR mix (Bio-Rad, Hercules, CA). Real-time primer sequences are shown in Online Table I. Immunoprecipitation RAW264.7 cells were collected in RIPA lysis buffer (sc-24948; Santa Cruz). Supernatants were immunoprecipitated with 5 µg of anti-AMPK overnight and then incubated with protein A sepharose 3 CL-4B (95016-992; VWR) for another 3 h at 4 °C. CHOP was detected as described for western blot analyses.
In vitro kinase assays.
In vitro kinase assays were done as described previously. 4 
DNA mutagenesis.
Myc-DDK-tagged ORF clone of CHOP (MR201400) was purchased from Origene Company (Rockville, MD). Ser30 of CHOP was mutated to Alanine or Glutamic acid by using the QuikChange kit (Stratagene), according to the manufacturer's instructions. 5, 6 Oligonucleotides used for point mutation are listed in Online Table II . All mutations were confirmed by DNA sequencing. Plasmid DNA was extracted on a large scale using Qiagen's EndoFree plasmid maxikit (12362) and transfected into RAW264.7 cells by using the X-tremeGENE HP DNA Transfection Reagent (06 366 236 001; Roche), according to the instructions provided by the manufacturer. After transfection, cells underwent 24-h incubation before receiving any additional treatments. Cells transfected with the expression WT DDK-CHOP served as controls.
Tissue collection, processing, and lesion analysis Anesthetized mice were perfused through the left ventricle with PBS under physiological pressure. The carotid arteries in the cuff were removed and embedded in optimal cutting temperature compound (Sakura Finetechnical, Tokyo, Japan), snap-frozen in liquid nitrogen, and stored at -80°C until use.
Intracuff lesions were evaluated by analysis of three serial cross-sections (6 m thickness) that were obtained at an interval of 0.3 mm. For morphometric analysis, the sections were stained with hematoxylin-eosin (H&E), and ruptured plaque is defined as a lesion of neointimal disruption with mural or occlusive thrombus.
Immunohistochemistry staining
Consecutive frozen sections were incubated in endogenous peroxidase and protein block buffer (DAKO), and then with primary antibodies overnight at 4°C. Slides were rinsed with washing buffer and incubated with labeled polymer-horseradish peroxidase-anti-mouse/anti-rabbit antibodies followed by DAB+ chromogen detection (DAKO). Immunohistochemical staining for -smooth muscle actin was performed with detection by Permanent Red (DAKO). After final washes, sections were counterstained with hematoxylin. All positive staining was confirmed by ensuring that no staining occurred under the same conditions with the use of non-immune rabbit or mouse control IgG. Sections were mounted and visualized using an OLYMPUS BX51 microscope.
Picrosirius red staining
Sections were stained with picrosirius red staining to determine the collagen content. The images were viewed by normal or polarized light.
Online Table I . Specific primers for quantitative RT-PCR. 
Gene name
